New Agency to Soon Replace French AFSSAPS
France has created a new agency, the National Agency for the Safety of Medicines and Health Products (MSNA), to replace its current regulatory agency, Afssaps.
The move was announced April 29 in France's Official Journal, which noted the new agency remains under development and the change will be effective in a few months.
MSNA will have a broader regulatory authority for monitoring and evaluation of health products, such as the development of independent research on product safety and requiring clinical studies against active comparators and placebo, Afssaps said in a statement.
The new agency will also have an operating budget greater than Afssaps (157 milliion Euros in 2012 vs. 125 million in 2010) and is financed exclusively by a state subsidy rather than through taxes or user fees from manufacturers.
Afssaps has been reeling from a series of scandals in recent months, including reports that the anti-diabetes drug Mediator was left on the market for a decade longer than was safe and its failure to stop defective breast implants manufactured by Poly Implant Prothese from being implanted into thousands of patients in France.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.
